Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 9, 2008, Pages 1647-1653

  Johnson, Jason L ^a   Sala Newby, Graciela B ^a   Ismail, Yasmin ^a   Aguilera, Concepción M ^a,b   Newby, Andrew C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Atherosclerosis; Foam cells; Macrophages; Plaque vulnerability; Tissue inhibitors of matrix metalloproteinases

Indexed keywords

MATRIX METALLOPROTEINASE 14; NEUTRALIZING ANTIBODY; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; MESSENGER RNA; MMP14 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BASEMENT MEMBRANE; CELL INVASION; CELL PROLIFERATION; CELL SUBPOPULATION; DOWN REGULATION; FOAM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RABBIT; ANIMAL; ATHEROSCLEROSIS; CELL CULTURE; CELL MOTION; ENZYMOLOGY; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; UPREGULATION;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; FOAM CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 14; RABBITS; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-3; UP-REGULATION;

EID: 51649101109     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.170548     Document Type: Article

References (38)

1. Newby AC. Dual role of matrix metalloproteinases (matrixins) in neointima formation and atherosclerotic plaque rupture. Physiol Rev. 2005; 85:1-31.
2. Tedgui A. Mallat Z. Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol Rev. 2006;86:515-581.
3. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res. 2006;69:625-635.
4. Boyle JJ, Weissberg PL, Bennett MR. Human Macrophage-Induced Vascular Smooth Muscle Cell Apoptosis Requires NO Enhancement of Fas/Fas-L Interactions. Arterioscler Thromb Vasc Biol, 2002;22: 1624-1630.
5. Johnson JL. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther. 2007; 5:265-282.
6. Galis ZS, Sukhova GK, Kranzhöfer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrixdegrading proteinases. Proc Natl Acad Sci USA. 1995;92:402-406.
7. Zaltsman AB, Newby AC. Increased, secretion of gelatinases A and B from, the aortas of cholesterol fed rabbits: Relationship to lesion, severity. Atherosclerosis. 1997;130:61-70.
8. Jeng AY, Chou M, Sawyer WK, Caplan SL, Linden-Reed JV, Jeune M, Prescott MF. Enhanced expression of matrix metalloproteinase-3, -12, and -13 mRNAs in the aortas of apolipoprotein E-deficient mice with advanced atherosclerosis. Ann NY Acad Sci. 1999;878:555-558.
9. Chase AJ, Bond M, Crook MF, Newby AC. Role of nuclear factor-KB activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol. 2002;22:765-771.
10. Thomas AC, Sala-Newby GB, Ismail Y, Johnson JL, Pasterkamp G, Newby AC. Genomics of foam cells and nonfoamy macrophages from rabbits identifies arginase-1 as a differential regulator of nitric oxide production. Arterioscler Thromb Vasc Biol. 2007;27:571-577.
11. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94: 2493-2503.
12. Zaltsman AB, George SJ, Newby AC. Increased, secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity. Arterioscler Thromb Vasc Biol. 1999;19:1700-1707.
13. Fabunmi RP, Sukhova OK, Sugiyama S, Libby P. Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells. Circ Res. 1998;83:270-278.
14. Rouis M, Adamy C, Duverger N, Lesnik P, Horellou P, Moreau M, Emmanuel F, Caillaud JM, Laplaud PM, Dachet C, Chapman MJ. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation. 1999;100:533-540.
15. Johnson JL, Baker AH, Oka K, Chan L, Newby AC, Jackson CL, George SJ. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: Involvement of macrophage migration and apoptosis. Circulation. 2006;113:2435-2444.
16. Verhoeven BAN, Velema E, Schoneveld AH, de Vries J, de Bruin P, Seldenrijk CA, de Kleijn DPV, Busser E, van der Graaf Y, Moll F, Pasterkamp G. Athero-express: Differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. Eur J Epidemiol. 2004;19: 1127-1133.
17. English JL, Kassiri Z, Koskivirta I, Atkinson SJ, Di Grappa M, Soloway PD, Nagase H, Vuorio E, Murphy G, Khokha R. Individual TIMP deficiencies differentially impact pro-MMP-2 activation. Journal of Biological Chemistry. 2006;281:10337-10346.
18. Doyle GAR, SaarialhoKere UK, Parks WC. Distinct mechanisms regulate TIMP-1 expression at different stages of phorbol ester-mediated differentiation of U937 cells. Biochemistry. 1997;36:2492-2500.
19. Gordon S. Macrophage heterogeneity and tissue lipids. J Clin Invest. 2007;117:89-93.
20. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25:677-686.
21. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, Pittet MJ. Ly-6Chi monocytes dominate hypercholesterolemiaassociated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007;117:195-205.
22. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA, Habenicht AJ, Randolph GJ. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117:185-194.
23. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007;6: 137-143.
24. Waldo SW, Li Y, Buono C, Zhao B, Billings EM, Chang J, Kruth HS. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol. 2008;172:1112-1126.
25. Baker AH, Zaltsman AB, George SJ, Newby AC, Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. J Clin. Invest. 1998;101:1478-1487.
26. Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. British Journal of Cancer. 1999;70: 1347-1355.
27. Kassiri Z, Oudit GY. Sanchez O, Dawood F, Mohammed FF, Nuttall RK, Edwards DR, Liu PP, Backx PH, Khokha R. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ Res. 2005;97:380-390.
28. Tian H, Cimini M, Fedak PWM, Altamentova S, Fazel S, Huang ML, Weisel RD, Li RK. TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction. J Mol Cell Cardiol. 2007;43:733-743.
29. Fata JE, Leco KJ, Voura EB, Yu HYE, Waterhouse P, Murphy G, Moorehead RA, Khokha R. Accelerated apoptosis in the TIMP-3deficient mammary gland. J Clin. Invest. 2001;108:831-841.
30. Ray BK, Shakya A, Turk. JR, Apte SS, Ray A. Induction of the MMP-14 gene in macrophages of the atherosclerotic plaque. Circ Res. 2004;95: 1082-1090.
31. Sithu SD, English WR, Olson P, Krubasik D, Baker AH, Murphy G, D'Souza SE. Membrane type 1-matrix metalloproteinase (MTl-MMP) regulates intracellular adhesion molecule-1 (ICAM-I) mediated monocyte transmigration. J Biol Chem. In press.
32. Luo XH, Liao EY, Liao HJ, Jin Y, Zhou HD, Huang G. Recombinant matrix metalloproteinase-14 catalytic domain induces apoptosis in human osteoblastic SaOS-2 cells. Journal of Endocrinological Investigation. 2003;26:1111-1116.
33. Langlois S, Di Tomasso G, Boivin D, Roghi C, Murphy G, Gingras D, Beliveau R. Membrane type 1-matrix metalloproteinase induces endothelial cell morphogenic differentiation by a caspase-dependent mechanism. Experimental Cell Research. 2005;307:452-464.
34. Kuge Y, Takai N, Ishino S, Temma T, Shiomi M, Saji H. Distribution profiles of membrane type-1 matrix metalloproteinase (MTl-MMP), matrix metalloproteinase-2 (MMP-2) and cyclooxygenase-2 (COX-2) in rabbit atherosclerosis: Comparison with plaque instability analysis. Biol Pharmaceut Bull. 2007;30:1634-1640.
35. Rajavashisth TB, Xu X-P, Jovinge S, Meisel S, Xu X-O, Chai N-N, Fishbein C, Kaul S, Cercek B, Sharifi BG, Shah PD. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques. Circ Res. 1999;99:3101-3109.
36. Schneider F, Sukhova GK, Aikawa M, Canner J, Gerdes N, Tang SMT, Shi GP, Apte SS, Libby P. Matrix metalloproteinase-14 deficiency in bone marrow-derived cells promotes collagen accumulation in mouse atherosclerotic plaques. Circulation. 2008;117:931-939.
37. Sithu SD, English WR, Olson P, Krubasik D, Baker AH, Murphy G, D'Souza SE. Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM- l)-mediated monocyte transmigration. J Biol Chem. 2007;282:25010-25019.
38. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993;69: 377-381.